



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARG5

Last Trade:	1.18
Trade Time:	1:33 PM ET Mar 22, 2018
Change:	0.00 (0.025%)
Day Range	1.15 - 1.20
52-Week Range	1.15 - 16.80
Volume	128,116

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 15, 2018

[Argos Announces Issuance of Patent Covering the Foundation[®] for Manufacturing its HIV Immunotherapy](#)

Feb 5, 2018

[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)

Jan 18, 2018

[Argos Announces One-for-Twenty Reverse Stock Split](#)

Jan 8, 2018

[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)

Nov 28, 2017

[Argos Provides Financial Update](#)

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Jul 6, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)